Immunosuppression for Dual Kidney Transplantation with Marginal Organs: The Old Is Better Yet
Immunosuppressive protocols in dual kidney transplantation (DKT) are based on calcinerurin inhibitors (CNI). We wonder whether a CNI‐free immunosuppression can improve outcome in older patients receiving a DKT with marginal donor organs. Thirty‐six were treated with CsA, MMF and prednisone (CsA grou...
Gespeichert in:
| Veröffentlicht in: | American journal of transplantation 2007-03, Vol.7 (3), p.639-644 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 644 |
|---|---|
| container_issue | 3 |
| container_start_page | 639 |
| container_title | American journal of transplantation |
| container_volume | 7 |
| creator | Cruzado, J. M. Bestard, O. Riera, L. Torras, J. Gil‐Vernet, S. Serón, D. Rama, I. Moreso, F. Martínez‐Castelao, A. Grinyó, J. M. |
| description | Immunosuppressive protocols in dual kidney transplantation (DKT) are based on calcinerurin inhibitors (CNI). We wonder whether a CNI‐free immunosuppression can improve outcome in older patients receiving a DKT with marginal donor organs. Thirty‐six were treated with CsA, MMF and prednisone (CsA group) and 42 with rATG, SRL, MMF and prednisone (SRL group). Incidence of delayed graft function and acute rejection was 44% and 11% in the CsA group, and 40% and 8% in the SRL group. CMV infection incidence was low in both protocols. Three‐year patient survival was 89% in the CsA and 76% in the SRL group. One‐ and 3‐year graft survival after censoring for dead with a functioning allograft was 94.2% and 94% in CsA and 95% and 90% in SRL, respectively. Renal function was similar in both groups whereas proteinuria was higher in the SRL group. Uninephrectomy due to graft thrombosis or urinary‐related complications was numerically higher in the SRL (21%) than in the CsA group (8%) (p = 0.13) and it was associated with renal failure and proteinuria. In DKT, a new induction immunosuppressive protocol based on rATG, SRL, MMF and prednisone does not offer any advantage in comparison to the old CsA, MMF and prednisone.
This study comparing two immunosuppressive protocols in patients receiving dual kidney transplants from extended criteria donors found that a protocol with rATG and sirolimus offered no advantages over a cyclosporine‐based protocol. |
| doi_str_mv | 10.1111/j.1600-6143.2007.01671.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70255372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70255372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4781-d2279046ad6caffd7365dd5bd75d67e11c11c98179122cf29194841d271b6dcc3</originalsourceid><addsrcrecordid>eNqNkUtPxCAUhYnR-P4Lho3upnKhhdbEhW_HR2YzLlwYwgDVTvoS2uj8e6kz0aUSknuT8124OQchDCSCcI7nEXBCRhxiFlFCRESAC4g-19D2j7D-07NkC-14PycEBE3pJtoKFUTM2DZ6GVdVXze-b1tnvS-aGueNw5e9KvF9YWq7wFOnat-Wqu5UN-gfRfeGH5V7LeoATdxrkE_w9M3iSWnw2ONz23XW4Wfb7aGNXJXe7q_qLnq6vppe3I4eJjfji7OHkY5FCiNDqchIzJXhWuW5EYwnxiQzIxLDhQXQ4WYpiAwo1TnNIIvTGAwVMONGa7aLjpbvtq55763vZFV4bcuwtG16LwWhScIE_ROkJI4hITyA6RLUrvHe2Vy2rqiUW0ggcshAzuVgrxyslkMG8jsD-RlGD1Z_9LPKmt_BlekBOFwBymtV5sFfXfhfLuUAKROBO11yH0VpF_9eQJ7dTYeOfQHxZqEu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20441506</pqid></control><display><type>article</type><title>Immunosuppression for Dual Kidney Transplantation with Marginal Organs: The Old Is Better Yet</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Cruzado, J. M. ; Bestard, O. ; Riera, L. ; Torras, J. ; Gil‐Vernet, S. ; Serón, D. ; Rama, I. ; Moreso, F. ; Martínez‐Castelao, A. ; Grinyó, J. M.</creator><creatorcontrib>Cruzado, J. M. ; Bestard, O. ; Riera, L. ; Torras, J. ; Gil‐Vernet, S. ; Serón, D. ; Rama, I. ; Moreso, F. ; Martínez‐Castelao, A. ; Grinyó, J. M.</creatorcontrib><description>Immunosuppressive protocols in dual kidney transplantation (DKT) are based on calcinerurin inhibitors (CNI). We wonder whether a CNI‐free immunosuppression can improve outcome in older patients receiving a DKT with marginal donor organs. Thirty‐six were treated with CsA, MMF and prednisone (CsA group) and 42 with rATG, SRL, MMF and prednisone (SRL group). Incidence of delayed graft function and acute rejection was 44% and 11% in the CsA group, and 40% and 8% in the SRL group. CMV infection incidence was low in both protocols. Three‐year patient survival was 89% in the CsA and 76% in the SRL group. One‐ and 3‐year graft survival after censoring for dead with a functioning allograft was 94.2% and 94% in CsA and 95% and 90% in SRL, respectively. Renal function was similar in both groups whereas proteinuria was higher in the SRL group. Uninephrectomy due to graft thrombosis or urinary‐related complications was numerically higher in the SRL (21%) than in the CsA group (8%) (p = 0.13) and it was associated with renal failure and proteinuria. In DKT, a new induction immunosuppressive protocol based on rATG, SRL, MMF and prednisone does not offer any advantage in comparison to the old CsA, MMF and prednisone.
This study comparing two immunosuppressive protocols in patients receiving dual kidney transplants from extended criteria donors found that a protocol with rATG and sirolimus offered no advantages over a cyclosporine‐based protocol.</description><identifier>ISSN: 1600-6135</identifier><identifier>EISSN: 1600-6143</identifier><identifier>DOI: 10.1111/j.1600-6143.2007.01671.x</identifier><identifier>PMID: 17217433</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Calcineurin Inhibitors ; Cardiovascular Diseases - prevention & control ; Cyclosporine ; Cyclosporine - therapeutic use ; Cytomegalovirus ; Delayed Graft Function - prevention & control ; Drug Therapy, Combination ; Female ; Graft Rejection - prevention & control ; Graft Survival ; Humans ; immunosuppression ; Immunosuppression Therapy - methods ; Kidney Failure, Chronic - surgery ; Kidney Transplantation - immunology ; Kidney Transplantation - mortality ; Male ; marginal donors ; Medical sciences ; Middle Aged ; mycophenolate mofetil ; Mycophenolic Acid - therapeutic use ; Pharmacology. Drug treatments ; Postoperative Complications - prevention & control ; Prednisone - therapeutic use ; rapamycin ; renal transplantation ; Risk ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system ; thymoglobulin ; Treatment Outcome</subject><ispartof>American journal of transplantation, 2007-03, Vol.7 (3), p.639-644</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4781-d2279046ad6caffd7365dd5bd75d67e11c11c98179122cf29194841d271b6dcc3</citedby><cites>FETCH-LOGICAL-c4781-d2279046ad6caffd7365dd5bd75d67e11c11c98179122cf29194841d271b6dcc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1600-6143.2007.01671.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1600-6143.2007.01671.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18611837$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17217433$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cruzado, J. M.</creatorcontrib><creatorcontrib>Bestard, O.</creatorcontrib><creatorcontrib>Riera, L.</creatorcontrib><creatorcontrib>Torras, J.</creatorcontrib><creatorcontrib>Gil‐Vernet, S.</creatorcontrib><creatorcontrib>Serón, D.</creatorcontrib><creatorcontrib>Rama, I.</creatorcontrib><creatorcontrib>Moreso, F.</creatorcontrib><creatorcontrib>Martínez‐Castelao, A.</creatorcontrib><creatorcontrib>Grinyó, J. M.</creatorcontrib><title>Immunosuppression for Dual Kidney Transplantation with Marginal Organs: The Old Is Better Yet</title><title>American journal of transplantation</title><addtitle>Am J Transplant</addtitle><description>Immunosuppressive protocols in dual kidney transplantation (DKT) are based on calcinerurin inhibitors (CNI). We wonder whether a CNI‐free immunosuppression can improve outcome in older patients receiving a DKT with marginal donor organs. Thirty‐six were treated with CsA, MMF and prednisone (CsA group) and 42 with rATG, SRL, MMF and prednisone (SRL group). Incidence of delayed graft function and acute rejection was 44% and 11% in the CsA group, and 40% and 8% in the SRL group. CMV infection incidence was low in both protocols. Three‐year patient survival was 89% in the CsA and 76% in the SRL group. One‐ and 3‐year graft survival after censoring for dead with a functioning allograft was 94.2% and 94% in CsA and 95% and 90% in SRL, respectively. Renal function was similar in both groups whereas proteinuria was higher in the SRL group. Uninephrectomy due to graft thrombosis or urinary‐related complications was numerically higher in the SRL (21%) than in the CsA group (8%) (p = 0.13) and it was associated with renal failure and proteinuria. In DKT, a new induction immunosuppressive protocol based on rATG, SRL, MMF and prednisone does not offer any advantage in comparison to the old CsA, MMF and prednisone.
This study comparing two immunosuppressive protocols in patients receiving dual kidney transplants from extended criteria donors found that a protocol with rATG and sirolimus offered no advantages over a cyclosporine‐based protocol.</description><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Calcineurin Inhibitors</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Cyclosporine</subject><subject>Cyclosporine - therapeutic use</subject><subject>Cytomegalovirus</subject><subject>Delayed Graft Function - prevention & control</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Graft Rejection - prevention & control</subject><subject>Graft Survival</subject><subject>Humans</subject><subject>immunosuppression</subject><subject>Immunosuppression Therapy - methods</subject><subject>Kidney Failure, Chronic - surgery</subject><subject>Kidney Transplantation - immunology</subject><subject>Kidney Transplantation - mortality</subject><subject>Male</subject><subject>marginal donors</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>mycophenolate mofetil</subject><subject>Mycophenolic Acid - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Postoperative Complications - prevention & control</subject><subject>Prednisone - therapeutic use</subject><subject>rapamycin</subject><subject>renal transplantation</subject><subject>Risk</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the urinary system</subject><subject>thymoglobulin</subject><subject>Treatment Outcome</subject><issn>1600-6135</issn><issn>1600-6143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtPxCAUhYnR-P4Lho3upnKhhdbEhW_HR2YzLlwYwgDVTvoS2uj8e6kz0aUSknuT8124OQchDCSCcI7nEXBCRhxiFlFCRESAC4g-19D2j7D-07NkC-14PycEBE3pJtoKFUTM2DZ6GVdVXze-b1tnvS-aGueNw5e9KvF9YWq7wFOnat-Wqu5UN-gfRfeGH5V7LeoATdxrkE_w9M3iSWnw2ONz23XW4Wfb7aGNXJXe7q_qLnq6vppe3I4eJjfji7OHkY5FCiNDqchIzJXhWuW5EYwnxiQzIxLDhQXQ4WYpiAwo1TnNIIvTGAwVMONGa7aLjpbvtq55763vZFV4bcuwtG16LwWhScIE_ROkJI4hITyA6RLUrvHe2Vy2rqiUW0ggcshAzuVgrxyslkMG8jsD-RlGD1Z_9LPKmt_BlekBOFwBymtV5sFfXfhfLuUAKROBO11yH0VpF_9eQJ7dTYeOfQHxZqEu</recordid><startdate>200703</startdate><enddate>200703</enddate><creator>Cruzado, J. M.</creator><creator>Bestard, O.</creator><creator>Riera, L.</creator><creator>Torras, J.</creator><creator>Gil‐Vernet, S.</creator><creator>Serón, D.</creator><creator>Rama, I.</creator><creator>Moreso, F.</creator><creator>Martínez‐Castelao, A.</creator><creator>Grinyó, J. M.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200703</creationdate><title>Immunosuppression for Dual Kidney Transplantation with Marginal Organs: The Old Is Better Yet</title><author>Cruzado, J. M. ; Bestard, O. ; Riera, L. ; Torras, J. ; Gil‐Vernet, S. ; Serón, D. ; Rama, I. ; Moreso, F. ; Martínez‐Castelao, A. ; Grinyó, J. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4781-d2279046ad6caffd7365dd5bd75d67e11c11c98179122cf29194841d271b6dcc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Calcineurin Inhibitors</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Cyclosporine</topic><topic>Cyclosporine - therapeutic use</topic><topic>Cytomegalovirus</topic><topic>Delayed Graft Function - prevention & control</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Graft Rejection - prevention & control</topic><topic>Graft Survival</topic><topic>Humans</topic><topic>immunosuppression</topic><topic>Immunosuppression Therapy - methods</topic><topic>Kidney Failure, Chronic - surgery</topic><topic>Kidney Transplantation - immunology</topic><topic>Kidney Transplantation - mortality</topic><topic>Male</topic><topic>marginal donors</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>mycophenolate mofetil</topic><topic>Mycophenolic Acid - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Postoperative Complications - prevention & control</topic><topic>Prednisone - therapeutic use</topic><topic>rapamycin</topic><topic>renal transplantation</topic><topic>Risk</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the urinary system</topic><topic>thymoglobulin</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cruzado, J. M.</creatorcontrib><creatorcontrib>Bestard, O.</creatorcontrib><creatorcontrib>Riera, L.</creatorcontrib><creatorcontrib>Torras, J.</creatorcontrib><creatorcontrib>Gil‐Vernet, S.</creatorcontrib><creatorcontrib>Serón, D.</creatorcontrib><creatorcontrib>Rama, I.</creatorcontrib><creatorcontrib>Moreso, F.</creatorcontrib><creatorcontrib>Martínez‐Castelao, A.</creatorcontrib><creatorcontrib>Grinyó, J. M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cruzado, J. M.</au><au>Bestard, O.</au><au>Riera, L.</au><au>Torras, J.</au><au>Gil‐Vernet, S.</au><au>Serón, D.</au><au>Rama, I.</au><au>Moreso, F.</au><au>Martínez‐Castelao, A.</au><au>Grinyó, J. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunosuppression for Dual Kidney Transplantation with Marginal Organs: The Old Is Better Yet</atitle><jtitle>American journal of transplantation</jtitle><addtitle>Am J Transplant</addtitle><date>2007-03</date><risdate>2007</risdate><volume>7</volume><issue>3</issue><spage>639</spage><epage>644</epage><pages>639-644</pages><issn>1600-6135</issn><eissn>1600-6143</eissn><abstract>Immunosuppressive protocols in dual kidney transplantation (DKT) are based on calcinerurin inhibitors (CNI). We wonder whether a CNI‐free immunosuppression can improve outcome in older patients receiving a DKT with marginal donor organs. Thirty‐six were treated with CsA, MMF and prednisone (CsA group) and 42 with rATG, SRL, MMF and prednisone (SRL group). Incidence of delayed graft function and acute rejection was 44% and 11% in the CsA group, and 40% and 8% in the SRL group. CMV infection incidence was low in both protocols. Three‐year patient survival was 89% in the CsA and 76% in the SRL group. One‐ and 3‐year graft survival after censoring for dead with a functioning allograft was 94.2% and 94% in CsA and 95% and 90% in SRL, respectively. Renal function was similar in both groups whereas proteinuria was higher in the SRL group. Uninephrectomy due to graft thrombosis or urinary‐related complications was numerically higher in the SRL (21%) than in the CsA group (8%) (p = 0.13) and it was associated with renal failure and proteinuria. In DKT, a new induction immunosuppressive protocol based on rATG, SRL, MMF and prednisone does not offer any advantage in comparison to the old CsA, MMF and prednisone.
This study comparing two immunosuppressive protocols in patients receiving dual kidney transplants from extended criteria donors found that a protocol with rATG and sirolimus offered no advantages over a cyclosporine‐based protocol.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17217433</pmid><doi>10.1111/j.1600-6143.2007.01671.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1600-6135 |
| ispartof | American journal of transplantation, 2007-03, Vol.7 (3), p.639-644 |
| issn | 1600-6135 1600-6143 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70255372 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Calcineurin Inhibitors Cardiovascular Diseases - prevention & control Cyclosporine Cyclosporine - therapeutic use Cytomegalovirus Delayed Graft Function - prevention & control Drug Therapy, Combination Female Graft Rejection - prevention & control Graft Survival Humans immunosuppression Immunosuppression Therapy - methods Kidney Failure, Chronic - surgery Kidney Transplantation - immunology Kidney Transplantation - mortality Male marginal donors Medical sciences Middle Aged mycophenolate mofetil Mycophenolic Acid - therapeutic use Pharmacology. Drug treatments Postoperative Complications - prevention & control Prednisone - therapeutic use rapamycin renal transplantation Risk Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system thymoglobulin Treatment Outcome |
| title | Immunosuppression for Dual Kidney Transplantation with Marginal Organs: The Old Is Better Yet |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T00%3A37%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunosuppression%20for%20Dual%20Kidney%20Transplantation%20with%20Marginal%20Organs:%20The%20Old%20Is%20Better%20Yet&rft.jtitle=American%20journal%20of%20transplantation&rft.au=Cruzado,%20J.%20M.&rft.date=2007-03&rft.volume=7&rft.issue=3&rft.spage=639&rft.epage=644&rft.pages=639-644&rft.issn=1600-6135&rft.eissn=1600-6143&rft_id=info:doi/10.1111/j.1600-6143.2007.01671.x&rft_dat=%3Cproquest_cross%3E70255372%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20441506&rft_id=info:pmid/17217433&rfr_iscdi=true |